Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting

Next Previous
Trial Profile

Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Dostarlimab (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Endometrial cancer
  • Focus Therapeutic Use
  • Acronyms DOMENICA

Most Recent Events

  • 10 Jul 2025 Status changed from recruiting to active, no longer recruiting.
  • 18 Jan 2024 Recruitment completion is expected on 1 Aug 2025, according to ISRCTN: Current Controlled Trials.
  • 06 Jun 2023 A protocol amendment is submitted to increase patient population (with extended eligibility criteria, PFS hypothesis) according to Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top